Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|July 25, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-08-02-2017
- Volume 12
- Issue 8
Recipharm and LIDDS Establish Industrial Manufacturing Capabilities for Prostate Cancer Drug
Author(s)Pharmaceutical Technology Editors
ipharm set up a manufacturing line at its facility in Sweden using LIDD’s NanoZolid technology.
Advertisement
Recipharm, a contract development and manufacturing organization (CDMO), and LIDDS have together set up a manufacturing line for LIDDS’ novel prostate cancer drug, Liproca Depot, which contains 2-hydroxyflutamide, at Recipharm’s facility in Solna, Sweden.
The manufacturing line is dedicated to the first product based on LIDDS’ innovative NanoZolid technology, which provides localized controlled release that can be sustained for up to six months. NanoZolid can integrate both small- and large-molecule drugs. Clinical trial material has already been produced, and the facility is ready for future commercial manufacturing of Liproca Depot or other pharmaceutical formulations based on the NanoZolid technology. The manufacturing line has been adapted for GMP production and uses a unique process invented by LIDDS that uses equipment that is new to the pharmaceutical industry.
”With the successful manufacturing performed at Recipharm, LIDDS can offer license agreements for Liproca Depot with the advantage of having validated production in place, saving both time and money for pharma companies. In addition, we now have an established manufacturing facility ready for other NanoZolid projects,” says Monica Wallter CEO of LIDDS.
Source:
Articles in this issue
about 9 years ago
New Reactors Spur Continuous API Manufacturingabout 9 years ago
New Lab Instruments Tackle Workflow Challengesabout 9 years ago
Lonza Launches New Biomanufacturing Complexabout 9 years ago
FDA to Lead International Effort to Secure the Supply Chainabout 9 years ago
Report: Dose CMOs Stuck in Idleabout 9 years ago
Catalent Adds Early Development Offerings to OptiForm Platformabout 9 years ago
Nitto Denko Avecia Announces Manufacturing Expansionabout 9 years ago
Alcami Relocates Headquarters to Research Triangle Park, NCover 9 years ago
Recro Gainesville Adds Manufacturing CapacityAdvertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Complying with International Pharmacopoeias
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5